Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 5:12 AM
Ignite Modification Date:
2025-12-25 @ 5:12 AM
NCT ID:
NCT00675727
Eligibility Criteria:
Inclusion Criteria:
* At least 18 years of age
* Ability to understand and the willingness to sign a written informed consent document
* Subject must have a pathologic diagnosis malignant melanoma (stage III or IV).
* Subject must have at least one of the following:
1. Melanoma that was previously treated with at least one complete or partial course of therapy for melanoma with either a poor to no response or evidence of disease progression;
2. Melanoma that cannot be treated with first-line therapies because of medical comorbidities/risk of toxicity; or
3. Melanoma that has not been treated with first-line therapies because of patient refusal.
* If melanoma is possibly resectable, the melanoma must have recurred despite at least two attempts at resection.
* The subject must have measurable disease, as defined by the presence of at least one measurable lesion, defined as having longest diameter greater than or equal to 20 mm by conventional measurement techniques (e.g., measurement of evaluable cutaneous metastases) or greater than or equal to 20 mm by imaging studies.
* Subject must have an ECOG performance status of 0, 1, or 2.
* Subject must have the ability to understand and provide informed consent that fulfills Institutional Review Board guidelines. Alternatively, if the subject is mentally incompetent for medical decision-making, a parent, legal guardian, or power of attorney has the ability to understand and provide informed consent that fulfills Institutional Review Board guidelines.
* Subject must be able to comply with office visits as required by the protocol.
* The effects of Investigational product on the developing human fetus is at the recommended therapeutic dose are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
Exclusion Criteria:
* Subjects with medical co-morbidities, which in the judgment of the investigator, place them at an unacceptable level of risk for participation in this study.
* Pregnant women, since the prenatal effects of CADI-05 have not been characterized.
* Subjects with HIV, AIDS, or chronic immunosuppression for organ transplantation.
* Subjects who are unable to comply with office visits as required by this protocol or would suffer great hardship by participating in the study.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in the study.
* Clinically significant active infection.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00675727
Study Brief:
Protocol Section:
NCT00675727